E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036909 |
E.1.2 | Term | Prostate cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036911 |
E.1.2 | Term | Prostate cancer recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036912 |
E.1.2 | Term | Prostate cancer stage 0 |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036917 |
E.1.2 | Term | Prostate cancer stage I |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036918 |
E.1.2 | Term | Prostate cancer stage II |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036919 |
E.1.2 | Term | Prostate cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036920 |
E.1.2 | Term | Prostate cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10062904 |
E.1.2 | Term | Hormone-refractory prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10071119 |
E.1.2 | Term | Hormone-dependent prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of enzalutamide on the pharmacokinetics (PK) of oxycodone following a single 15 mg oral dose of normal-release oxycodone in men with prostate cancer, expressed in Cmax and AUC0-t. |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate the effect of enzalutamide on the pharmacokinetics (PK) of oxycodone following a single 15 mg oral dose of normal-release oxycodone in men with prostate cancer, expressed in AUC0-∞ and t1/2. 2. To investigate the effect of enzalutamide on the pharmacokinetics (PK) of oxycodone its metabolites noroxycodone, oxymorphone and noroxymorphone following a single 15 mg oral dose of normal-release oxycodone in men with prostate cancer, expressed in Cmax, AUC0-t, AUC0-∞ and t1/2.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Males aged ≥ 18 years; - Diagnosed prostate cancer; - Treated with enzalutamide 160 mg once daily for 40 days (arm 1) |
|
E.4 | Principal exclusion criteria |
- a body mass index (BMI) outside the range of 18 to 30 kg/m2; - known metastases in the liver that would affect drug metabolism; - Child-Pugh classification B or C that would affect drug metabolism; - known CYP3A4 or CYP2D6 polymorphisms that would affect drug metabolism (patients with a known CYP3A4 or CYP2D6 polymorphism afterwards will be replaced); - known moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that would affect drug metabolism; - gastrointestinal disorders that would potentially alter absorption; - previous gastric bypass or gastric band surgery; - known allergy, hypersensitivity or intolerance to normal-release oxycodone; - a history of drug abuse or treatment for abuse; - dose-reduction or ≥5 successive days of treatment interruption of enzalutamide within 40 days prior to the study day (arm 1); - treatment with enzalutamide within 40 days prior to the study day (arm 2); - use of oxycodone normal-release within 48 hours prior to oxycodone intake or use of oxycodone extended-release within 4 days prior to oxycodone intake; - use of other medication that would affect oxycodone metabolism, see section 5.2 and appendix B; - use of other medication that would affect enzalutamide metabolism, see section 5.2 and appendix B (arm 1). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Maximum serum concentration (Cmax) and Area under the serum concentration versus time curve from time zero to the time (t) corresponding to the last quantifiable concentration (AUC0-t) of oxycodone |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Plasma sampling at t=0.5, 1, 1.5, 2, 3, 5, 8 hours after intake of oxycodone. Evaluation of the endpoint will be done after completion of all plasma samples. |
|
E.5.2 | Secondary end point(s) |
1. Maximum serum concentration (Cmax) of noroxycodone, oxymorphone and noroxymorphone; 2. Area under the serum concentration versus time curve from time zero to the time (t) corresponding to the last quantifiable concentration (AUC0-t) of noroxycodone, oxymorphone and noroxymorphone; 3. Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase (AUC0-∞) of oxycodone and its metabolites noroxycodone, oxymorphone and noroxymorphone; 4. Terminal half-life (t1/2) of oxycodone and its metabolites noroxycodone, oxymorphone and noroxymorphone.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Plasma sampling at t=0.5, 1, 1.5, 2, 3, 5, 8 hours after intake of oxycodone. Evaluation of the endpoint will be done after completion of all plasma samples. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Oxycodone taken in prostate cancer patients treated vs not treated with enzalutamide |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | |